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Transforming growth factor beta (TGF-) is a major
promoter of diabetic nephropathy. While TGF-I is
the most abundant renal isoform, types 2 and 3 are
present as well and have identical in vitro effects.
Whole kidney extracts were studied 2 weeks after
induction of streptozocin diabetes and in control
rats. Mean glomerular area was 25% greater in the
diabetic animals. TGF-I showed a 2-fold increase
in message with a 3-fold increase in protein. TGF-2
mRNA increased approximately 6% while its
protein doubled. TGF--message increased by 25%,
producing a 35% increase in its protein. TGF--
inducible gene H3 mRNA was increased 35% in the
diabetic animals, consistent with increased activity
of this growth factor. All isoforms of TGF- are
increased in the diabetic rat kidney. Future studies
need to address the specific role that each isoform
plays in diabetic nephropathy as well as the impact
of therapies on each isoform.
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INTRODUCTION
Transforming growth factor beta (TGF-) has
been implicated in virtually every progressive
renal disease studied to date. [1,2] Diabetic
nephropathy is no exception. [3-6] Both dia-betes
in vivo and a high glucose environment in vitro
increase levels of mRNA for TGF-I in the
kidney. [-1 Blockade of TGF- effects prevents
diabetic renal hypertrophy in experimental
models of diabetes. [7,8]
Most studies have assessed only TGF-31, the
most abundant renal isoform of this growth
factor. The mammalian kidney also produces
isoforms 2 and 3. One study has examined these
isoforms in human biopsy specimens from a
variety of kidney diseases. [9] All diseases
associated with increased extracellular matrix,
such as diabetes, showed increased immunos-
taining for all 3 isoforms in the glomeruli and in
the tubulointerstitium. In situ hybridization was
also increased for all isoforms, although diabetic
specimens were not studied with this technique.
Hill et al., recently found that TGF-31, TGF-2,
and the type II TGF- receptor (TGFq3RII) all
varied over 6 months in 2 experimental models
of diabetes. [1]
While equivalent in vitro, these isoforms have
distinct functions in vivo, as demonstrated by the
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different phenotypes produced by knock-out
mice for each isoform [11-141 and different effects
in wound healing. [5] The present study shows
that mRNA and protein for all 3 isoforms
increase early in the course of streptozocin
diabetes in the rat.
RESEARCH DESIGN AND METHODS
Animals
Twenty male Sprague-Dawley rats, approxi-
mately 150 gm body weight and 6 to 8 weeks
old, were divided into 2 groups. One group was
injected intraperitoneally on day 0 with STZ,
65mg/kg body weight (STZ). The second group
received a similar volume of normal saline and
served as controls (SC). The animals had
spontaneously voided urine collected 48 to 72
hours after injection to determine the presence
or absence of glycosuria as an indicator of DM.
No insulin was administered to these animals.
They had free access to standard rat chow and
tap water throughout the study.
During the final 48 hours of the experiment,
animals were housed in metabolic cages for the
collection of 24-hour urine specimens. On the
fourteenth day after injection, the rats were
anesthetized with pentobarbital. Plasma was
collected by cardiac puncture. The kidneys
were then excised, weighed, and processed
for further study. One kidney was snap-frozen
in liquid nitrogen and stored at -70 C until
needed for isolation of protein and RNA.
The other kidney was immersed in Histo-
Choice MBTM (Amresco, Solon, OH). The Insti-
tutional Animal Care and Use Committee
of the University of Nebraska approved all
studies.
Biochemical Studies on Plasma and Urine
Plasma glucose was measured using a hexoki-
nase end-point method (Sigma, St. Louis, MO).
Urine albumin was assessed with competitive
ELISA (Nephrat, Exocell, Inc., Philadelphia, PA).
TGF- Protein Quantitation
After thawing, protein was extracted from
100mg of renal tissue using T-PER (Pierce,
Rockford, IL). TGF-I and TGF-2 were then
measured by ELISA (ErnaxTM Promega Cor-
poration, Madison, WI). These assay systems
measure in the range of 32-1,000pg/ml of the
growth factor. TGF-3 was measured with an
ELISA developed by our laboratory using
antibodies and reagents from R&D Systems
(Minneapolis, MN). Results were linear from 32
to 1,000pg/ml, similar to the sensitivity of the
commercial kits. ELISA assays were run in
duplicate. All ELISA assays have coefficients of
variation <4.5% in our laboratory. Total protein
was assessed using the Coomassie method (also
from Pierce). Results are reported as pg of TGF-
f per txg of total protein.
RNA Analysis
Tissue was stored at -70 until the time of analy-
sis. Approximately 100mg of tissue was homo-
genized and total RNA extracted using Trizol
Reagent (Gibco BRL, Grand Island, NY).
Semiquantitative reverse-transcriptase PCR was
performed. The primers were designed using
the published sequences of rat TGF-I, TGF-2,
TGF-3, TGF- inducible gene h3 (f3ig-H3), and
(-tubulin in the GeneFisher Team program
(http://bibiserv.techfak.uni-bielefeld.de). This
produced 8 primer pairs for each substance. A
primer set with the least difference in melting
temperature between the forward and reverse
sequences was selected, then cross-checked for
specificity for the rat mRNA sequence using
Blast Query Sequence Search (http://www.
ncbi.nlm.nih.gov). Specificity of the PCR pro-
duct was confirmed by Northern blot analysis
on rat liver and sequencing of the PCR product.
Sequences used were TGF-I: 5’TGTCCG-
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GCAGTGGCTGAAC and 5’GGCTT CGCACC-
CACGTAGT; TGF-2: 5’CCAAAGGGGTA-
CAATGCTAAC and 5’CGCGGACGATCATG
TTGGAAA; TGF-3: 5’CACAGCA CGGT-
GCTTGGACT and 5’CTGGCCTTCA CCTGA-
CCACT; [3ig-H3: 5’CTCCATCACACTCAGGG
GAA and 5’TTGGATCCCTCCA AACACGG;
and o-tubulin: 5’AAGAAGTCCAAGCTGGAG
TTC and 5’GTTGGTCTGGAATTCTGTCAG.
cDNA was fractionated by electrophoresis
through a 1% agarose gel. Optical densities of
the bands were determined using GelDoc with
Multi-Analyst software (BioRad Laboratories,
Hercules, CA). Results are measured as the ratio
of the optical density of the band of interest
to the [-tubulin band. After dividing each raw
ratio by the mean or median of the control
group, results are reported as the percentage of
controls.
Histologic Studies
Portions of each kidney were paraffin embedded
and sectioned at 4p,m. After removing the wax,
endogenous peroxidase was quenched with 10%
H202. The tissue was then blocked with normal
goat and rabbit sera. The primary antibody was
then applied at a 1:500 dilution for 1 hour at
37C. A secondary antibody, either anti-goat or
anti-rabbit conjugated to peroxidase (Chemicon
International, Inc, Temecula, CA), was then
applied for 20 minutes at 37C. The peroxidase
was then localized with 3-amino-9-ethylcar-
bazole (also from Chemicon). The slides were
counterstained with Mayer’s hematoxylin then
coverslipped with Crystal/Mount (Biomeda,
Foster City, CA). Primary antibodies included
anti-TGF-[31 (Santa Cruz Biotechnology, Santa
Cruz, CA), anti-TGF-62, and anti TGF-[33 (R&D
Systems, Minneapolis, MN).
Photomicrographs were captured using a
digital imaging system at a final magnification of
720, and 5 micrographs per animal were scored
by a single observer (PHL) who was masked
to the identity of the samples. Glomeruli and
tubules were graded on a scale of 0 to 4 on two
occasions, and the mean score used for analysis.
In addition, low-power micrographs (magnifica-
tion 180) of at least 20 glomerular profiles were
captured and used to determine mean glomeru-
lar profile area, an index of glomerular
volume.j16, 17] Area of each profile was measured
using ScionImage Beta 3b software (Scion
Corporation, Frederick, MD). Final magnification
was determined via stage micrometry in all cases.
Statistical Analysis
Values not normally distributed are expressed as
median (25th, 75th percentiles); normally dis-
tributed parameters are shown as mean + stand-
ard deviation. Data were examined with t tests if
normally distributed or Mann-Whitney rank sum
tests if the distribution failed the normality
test. P<0.05 was considered significant for all
comparisons. All statistical analyses were
performed with SigmaStat 2.0 (SPSS Science,
Chicago, IL).
RESULTS
All rats in the STZ group had moderate to large
glycosuria by dipstick 48 to 72 hours after
receiving the injection; SC rats were negative at
that time. By the end of 2 weeks, rats in the STZ
group had lower body weight than those in the
control group (Tab. I). Kidney weight tended to
be higher in the STZ animals, but this did not
reach statistical significance (p 0.06; power
0.34). Mean glomerular area was significantly
greater in diabetic animals (Tab. I). Plasma
glucose was significantly higher in diabetic
animals, as expected (Tab.I). Urinary albumin
excretion rate was not different during this short
duration of diabetes (Tab. I).
TGF-[31 mRNA was elevated in the STZ
group, as expected (Fig. 1). Smaller but statisti-
cally significant increases in message for TGF-[32
and TGF-63 were also demonstrated (Fig. 1).
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TABLE General characteristics
Saline controls (n 10) STZ diabetes (n 10)
Weight, gm 283 19 247 15"
Kidney weight, gm 1.07 0.14 1.23 _+ 0.22
Mean glomerular area, pm 6566 785 8206 1122"
Plasma glucose, mmol/1 8.1 (7.4, 8.7) 21.1 (20.4, 22.2)*
Urine albumin, mg/24 hours 3.4 (1.6, 6.7) 4.8 (1.2, 9.1)
*p 0.001 vs. saline controls.




















FIGURE 2 Whole kidney protein levels for total (active +
latent) TGF-6 isoforms after 2 weeks of streptozocin diabetes
in the rat. All 3 isoforms are significantly increased by
diabetes. Error bars designate I standard deviation.
FIGURE Whole kidney expression of mRNA for TGF-6
isoforms after 2 weeks of streptozocin diabetes in the rat. All
3 isoforms are significantly increased by diabetes: TGF-61 by
92%, TGF-62 by 6%, and TGF-63 by 25%. Shaded areas show
the 10th through 90th percentiles with a line at the median.
Error bars designate the 5th.and 95th percentiles. Outlier
data points are filled circles. A gel with representative
samples is shown.
Protein levels for these growth factors were also
increased (Fig. 2). Total TGF-[31 was approxi-
mately 3 times saline controls, and TGF-62
values were doubled by STZ diabetes. TGF-[33
increased approximately 35% in animals with
STZ diabetes (Fig. 2). This increase in TGF-6’s
was accompanied by an increase in message for
[3IG-H3 (SC 100 5% vs. STZ 135 5%; p 0.001).
Immunohistochemistry for TGF-[31 and TGF-
[33 showed no differences in localization of the
growth factor proteins, Semiquantitive scores
for glomerular TGF-[31 were modestly increased
in the STZ DM group (Tab. II). TGF-[32 general-
ly localized to the glomerulus and periglomeru-
lar tubules and blood vessels. Both glomerular
and tubular scores were increased by STZ DM
(Tab. II). Representative photomicrographs are
shown as well (Fig. 3).
DISCUSSION
All three mammalian isoforms of TGF-[3 are
increased in the rat kidney after 2 weeks of STZ
diabetes, a period of renal and glomerular
hypertrophy. Since no differences in the effects
of these growth factors have been demonstrated
in vitro, all may be playing a role in the patho-
genesis and progression of this nephropathy.
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TABLE II Immunohistochemistry
Saline controls (n 10) STZ diabetes (n 10)
TGF-[31
Glomeruli 1.1 0.2 1.6 0.5*
Tubules 3.0 +__ 0.2 3.2 +__ 0.5
TGF-[2
Glomeruli 1.1 0.3 1.7 0.5*
Tubules 1.7 0.4 2.4 0.6*
TGF-3
Glomeruli 1.6 0.5 1.7 _+ 0.5
Tubules 3.4 0.8 3.1 0.6
*p 0.02 vs. saline controls.
*p < 0.01 vs. saline controls.
Values shown as mean standard deviation.
Given the different roles of these isoforms in
renal development, each may be playing a very
specific role in diabetic renal hypertrophy. [11-14]
Most studies of TGF-[3 suppression to date
have used nonspecific measures that may sup-
press the production or function of all isoforms
of this growth factor. [7,18,19] These studies
FIGURE 3 Representative immunohistochemistry studies
for saline controls (SC) and streptozocin diabetes (STZ DM)
for all isoforms of TGF-[3.
suggest that TGF-[3 contributes to diabetic renal
hypertrophy, primarily the result of proximal
tubular growth. [7] Han et al., have shown
that specific blockade of TGF-[I production in
the proximal tubule with anti-sense oligonu-
cleotides does attenuate renal hypertrophy;
however, renal weight is not suppressed to
levels seen in nondiabetic mice. [8] While this
could be due to the incomplete suppression of
TGF-I production, it may also reflect the
function of other isoforms of TGF-[3 or other
growth factors in the diabetic animals.
While equivalent in vitro, these isoforms of
TGF-f are not the same in vivo. Knock-out mice
for TGF-[31 are phenotypically normal at birth,
but rapidly succumb to an autoimmune multi-
system inflammatory syndrome. [11] If rescued
from the autoimmune syndrome, animals may
be at risk of bowel tumors, depending on the
background strain. [21 TGF-[32 null mice exhibit
a wide-range of abnormalities, including
cardiac, lung, craniofacial, limb, spinal, eye, ear,
and urogenital defects. [12] The latter include a
variety of renal abnormalities. They succumb
rapidly after birth to respiratory failure. TGF-[33
null mice exhibit respiratory failure and cleft
palate without craniofacial abnormalities. [13,141
The mechanism of clefting is due to altered
cellular adhesion. Thus, the mammalian TGF-[3
isoforms appear to be functionally differ-
ent during embryogenesis. In rodent wound
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healing, inhibition of TGF-f31 with antibody
reduces scar formation, while similar treatment
against TGF-f32 has little effect. [15] In contrast,
exoge-nous addition of TGF-f33 into the wound
reduced scarring. [151 In this post-natal model,
these isoforms seem to have different effects.
Translational efficiency is also different for the
three forms of TGF-. [21] TGF-f31, while most
abundant in the kidney, is translated inefficiently
compared to TGF-f32. Our data would support
this in the diabetic kidney, since a 2-fold increase
in TGF-f31 mRNA resulted in a 3-fold increase in
total TGF-f31 protein, while a 6% increase in TGF-
f32 message produced a doubling of total TGF-f32
protein. Alternatively, the differences demonstrat-
ed may be due to changes in the processing or
metabolism of the peptide. Translational efficiency
has not been reported for TGF-f33. In our study, a
25% increase in message resulted in an increase in
total TGF-f33 protein of approximately 35%. This
may reflect relatively inefficient translation of this
growth factor, although additional studies are
required to confirm this speculation.
Recently, Hill et al., published the first paper
examining all 3 isoforms of TGF- in the kid-
neys of animals with experimental diabetes. [1]
Their results differ from ours, probably as a
result of methodologic differences. Their first
step was immunohistochemistry of all 3 TGF-f3
isoforms. Only those components of the TGF-
system showing major changes by immunohis-
tochemistry were further studied. Our experi-
ments showed rather subtle differences in
TGF-f31 and TGF-2 immunolocalization and
no differences in TGF-f33 after 14 days of
STZ DM. Our quantitative studies of all 3
isoforms suggest that immunohistochemistry
may be a poor quantitative screening tool for
this growth factor family, at least using the
methods described.
Our study also found increased message for
TGF-f31, as other investigators have previously
described; [7,8,22] Hill et al., report stable levels at
day 14 in their study. [1] Only 2 animals were
studied at this time point in their experiments.
While mRNA was consistently elevated over
controls in our study, there was a great deal of
variability in TGF-I expression, much more
than for the other isoforms. We also showed an
increase in TGF-31 protein which was not
apparent in the work of Hill et al. Our study
used ELISA to measure protein, while the earlier
study relied on Western blotting of only 3
animals. Given the variability in TGF-f31 protein
levels, it is possible that their results were due to
technique differences and small sample size.
We cannot rule-out cross-reactivity of the
isoforms in our ELISA measurements. While
the antibodies used in these assays reportedly
show <5% cross-reactivity among human
isoforms, cross-reactivity has not been assessed
in the rat. While our protein levels appear
similar in the graph (Fig. 2), levels of these
isoforms did not correlate significantly (r<0.3),
suggesting at least some degree of specificity.
Further study using antibodies with docu-
mented specificity in the rat will be needed to
confirm these results.
As in our experiment, significant differences
in message and protein for TGF-f32 were
demonstrated early in the course of STZ DM in
the work of Hill et al. Given the importance of
TGF-f32 in normal renal growth and develop-
ment, [12] it seems likely that this isoform plays a
major role in the early pathologic renal growth
of STZ DM. This same group has now shown
that TGF-f32 blockade may prevent prosclerotic
changes in the kidney after 2 weeks of STZ
DM. [231 Even though changes in levels of mRNA
and protein for this growth factor are small, it
has important physiologic effects in the diabetic
kidney.
TGF-f32 mRNA and protein have generally
been found in the juxtaglomerular apparatus,
localized with renin. [24,25] This may be a criti-
cal area for TGF-f3 production to influence
glomerular growth and composition. Wogensen
et al., have shown that mice transgenic for TGF-
31 under control of the Ren-1C promotor over-
produced this isoform in the juxtaglomerular
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apparatus. [261 After 3-5 months of age these
mice showed increased PAS-positive material
in the glomeruli, similar to the diffuse mesan-
gial expansion of diabetic glomerulopathy. After
5 months of age, accumulation of interstital
extracellular matrix and tubular atrophy could
be demonstrated. Thus, extremely localized
overexpression of TGF-f3 could result in sig-
nificant nephropathic lesions. TGF-f33 mRNA
and protein are much more widely distributed
in the kidney than TGF-2; [27] further study
wili be necessary to determine whether the
"statistically-significant" differences shown in
the present study also result in "physiologi-
cally-significant" differences in the diabetic rat
kidney.
We also cannot completely exclude the possi-
bility that our findings are the result of STZ
nephrotoxicity rather than the diabetic state. By
two weeks, STZ has been cleared by the rat. We
have attempted to use 5-thio-D-glucose, an
inhibitor of STZ, to examine this question in
the past; however, injection of the inhibitor
alone resulted in levels of TGF-f31 mRNA and
protein similar to those seen in rats with dia-
betes. [28] Injection of inhibitor plus STZ was not
additive. Hill et al., studied another model of
diabetes, the biobreeding rat, which devel-ops
diabetes spontaneously. [10] The pattern of
expression of the TGF- isoforms was quite
similar throughout their study period to that
for STZ DM. Thus, it seems likely that these
findings result from diabetes and not direct
STZ toxicity.
It has been suggested that TGF-f3 is the most
appropriate therapeutic target in diabetic kid-
ney disease. [4] Most studies to date have con-
centrated on TGF-31. While it is the most
abundant renal isoform of this growth factor,
smaller but significant increases in mRNA and
protein for isoforms 2 and 3 occur as well.
Future studies need to address specific roles
that these isoforms may play in diabetic kidney
disease and the effect of therapies on all forms
of TGF-f3.
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